ipx203
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
2
Earliest trial started Nov 1, 2015 (NCT02271503)
Timeline
Indications
Studied for
Mechanism of action
- Adaptor-associated kinaseINHIBITOR
AAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ipx203
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07138560 | Phase 4 | Jul 24, 2025 | Amneal Pharmaceuticals, The Cleveland Clinic |
| NCT06765668 | Phase 4 | Jan 31, 2025 | Amneal Pharmaceuticals, Impax Laboratories |
| NCT03877510 | Phase 3 | Apr 3, 2019 | Impax Laboratories |
| NCT03670953 | Phase 3 | Oct 31, 2018 | Impax Laboratories |
| NCT02271503 | Phase 2 | Nov 1, 2015 | Impax Laboratories |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Impax Laboratories | For profit | 4 | 4 | 3 | 2015 |
| Amneal Pharmaceuticals | For profit | 2 | 0 | 1 | 2025 |
| The Cleveland Clinic | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1